Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoStart with Pro — $79/mo
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Material AgreementItem 1.01 · 8-KMEDIUM RiskPositive

BIO ESSENCE CORP.

bioessence.com
Filed: Apr 24, 2026Irvine, CaliforniaCIK: 0001723059Healthcare
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Bio Essence Corp. acquired MediFlow AI software from Zhituo Software for $3.5 million in common stock, enhancing its technological capabilities and asset portfolio through a material definitive agreement.

Key Takeaways

Bio Essence Corp. completed an Asset Purchase Agreement to acquire MediFlow AI software including source code, system architecture, and technical data

Compensation structure involves issuance of $3.5 million in common stock, subject to Board of Directors approval

2 more takeaways

Filing Overview

Form Type8-K
Filing DateApr 24, 2026
Item1.01
CategoryMaterial Agreement
CIK0001723059
Accession #0001723059
Risk LevelMEDIUM
SentimentPositive
Signalopportunity
Topics
acquisitionai technologymaterial agreement

What This Means

The company entered into a significant agreement that could materially affect its business. This often signals new partnerships, licensing deals, or major contracts.
View Full Filing on SEC.govBrowse More Filings